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Abstract. Hypothesizing that non-significant cerebrovascular lesions on structural brain imaging lead to overdiagnosis of a
vascular etiology of dementia as compared to autopsy-confirmed diagnosis, we set up a study including 71 patients with autopsy-
confirmed diagnoses. Forty-two patients in the population (59%) appeared to have definite Alzheimer’s disease (AD), whereas
29 (41%) had a non-AD dementia form. The panel clinically diagnosed possible or probable vascular dementia (VaD) in 27
(38%) patients, whereas only five (19%) patients (p = 0.017) had an autopsy-confirmed diagnosis of VaD. Patients with vascular
lesions on structural brain imaging were often misdiagnosed as possible or probable VaD as compared to autopsy-confirmed
diagnosis.
Keywords: Alzheimer’s disease, brain imaging, dementia, differential dementia diagnosis, magnetic resonance imaging, vascular
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INTRODUCTION
By performing a clinical diagnostic dementia
work-up in elderly patients, frequently concomitant
diseases or abnormalities on technical examinations
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are observed [1, 2]. It is often difficult to judge whether
these concomitant factors are clinically relevant and
thus contribute to the dementia syndrome. This is espe-
cially the case with ischemic lesions on structural brain
imaging in elderly, which leads to difficulties to differ-
entiate between Alzheimer’s disease (AD), vascular
dementia (VaD), and AD with clinically significant
cerebrovascular disease (CVD) [3, 4]. The diagnosis
of VaD, and its differentiation from AD, is based on
the presence of vascular risk factors, neuroimaging,
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and clinical features such as acute onset and stepwise
progression.
In order to test the hypothesis that non-significant
cerebrovascular lesions on structural brain imag-
ing lead to overdiagnosis of a vascular etiology of
dementing disorders, this study determined the clinical
dementia diagnosis of a standard dementia work-up as
compared to autopsy-confirmed diagnoses.
MATERIALS AND METHODS
Study population
Seventy-one demented patients with autopsy-
confirmed diagnoses were included. Patients were
recruited through the Memory Clinic of Hospital Net-
work Antwerp (n = 64) and through centers referring to
the Biobank of the Institute Born-Bunge (n = 7). Based
on a presentation (by BF) of the information gathered
during the clinical diagnostic work-up at enrollment
in the study, a panel of three neurologists experienced
with dementia (JG, PPDD, SE) made a consensus clin-
ical dementia diagnosis. The panel was blinded for the
clinical diagnoses that were mentioned in the clinical
files of the included patients as well as for the neu-
ropathological diagnoses. The panel was provided with
clinical information, such as date of birth, age, gen-
der, history of past illnesses, social history, onset and
history of presenting complaint, familial history, med-
ication, physical examination, clinical neurological
examination, a complete neuropsychological exami-
nation including (among others) Mini-Mental State
Examination scores (MMSE) [5], brain magnetic res-
onance imaging (MRI), and/or computed tomography
(CT) scan.
This study was approved by the ethics committee of
the UAntwerp, Antwerp, Belgium.
Clinical diagnostic criteria
Clinical diagnoses were based on standard clinical
diagnostic criteria, allowing the panel to label each
clinical diagnosis as probable or possible depending
on the likelihood of it being the cause of dementia.
The diagnosis of probable AD was made according
to the NINCDS-ADRDA criteria [6]. The combination
of AD and CVD was diagnosed when patients fulfilled
the criteria of probable AD according to NINCDS-
ADRDA and, in addition, displayed CVD on brain CT
and/or MRI that, however, did not meet the criteria
of relevant CVD according to NINDS-AIREN criteria
of [7], thus excluding multiple large-vessel infarcts,
strategically placed infarcts, multiple basal ganglia,
and white matter lacunes or extensive white matter
lesions. VaD was diagnosed according to the NINDS-
AIREN criteria [7]. For the diagnosis of probable
frontotemporal dementia (FTD), criteria described
by Neary [8] were applied. Dementia with Lewy
bodies (DLB) was diagnosed using the clinical diag-
nostic criteria of McKeith [9]. Parkinson’s disease
dementia (PDD) was diagnosed when patients with
idiopathic Parkinson’s disease (PD) developed demen-
tia following a dementia-free interval of at least two
years. The criteria for the diagnosis of idiopathic PD
included the presence of at least two out of four motor
manifestations that characterize the disease and an
insidious onset [10]. Creutzfeldt-Jakob disease (CJD)
was diagnosed according to the diagnostic criteria of
Weber [11].
Neuropathological criteria
All pathological diagnoses were established accord-
ing to standard neuropathological criteria by the same
neuropathologist (JJM). Although the neuropatholo-
gist was blinded for the consensus diagnoses of the
clinical panel, he had access to all neuroimaging data.
For the diagnosis of AD, VaD, and DLB the neu-
ropathological criteria of Montine [12] were applied.
FTD was neuropathologically diagnosed according to
the Cairns criteria [13] and Mackenzie criteria [14,
15]. CJD was diagnosed according to Markesbery [16].
Neuropathology was performed on the right hemi-
sphere of the brain.
Categorization of diagnoses
Subjects neuropathologically diagnosed as AD or
AD with CVD were pooled in the AD group whereas
VaD and other dementias were pooled in the NONAD
group.
Statistical analyses
To describe and analyze our entire cohort categor-
ical variables were analyzed with a chi-square test,
and percentages were reported. Demographic compar-
isons were analyzed with unpaired t-tests, or in case
of no normal distribution a Mann Whitney U test was
used, and mean values with standard deviation were
reported. For all analyses, p-values below 0.05 were
considered significant. All statistical analyses were
performed using IBM SPSS Statistics 20.
E. Niemantsverdriet et al. / Structural Brain Imaging for Dementia Work-Up 1041
RESULTS
Population (Table 1)
Of the 71 patients, 38 were male (54%) and 33
were female (46%). There was no significant dif-
ference in the proportion of gender in the AD and
NONAD patient groups. Definite AD was diagnosed
in 42 patients (59%), whereas 29 (41%) patients had
a NONAD dementia: VaD (n = 6), FTD (n = 9), DLB
(n = 10), and CJD (n = 4). The NONAD group was sig-
nificantly younger than the AD group, for both age
at inclusion and age at death. MMSE scores were
not significantly different comparing both groups. The
interval between inclusion and autopsy was in most
cases short (as 66% of the patients died within one year
following inclusion), likewise as the interval between
last clinical evaluation and autopsy. No significant dif-
ferences were observed comparing intervals between
inclusion/last clinical evaluation and autopsy between
AD and NONAD groups. Structural neuroimaging data
were available for all patients: CT (n = 47) or MRI
(n = 24) brain scans.
Clinical dementia diagnoses as compared to
autopsy-confirmed definite dementia diagnoses
In total, six patients were neuropathologically diag-
nosed with VaD (8%). The panel clinically diagnosed
possible or probable VaD in 27 (38%) patients (with
or without concomitant AD or DLB). Of those 27
patients, diagnosis of VaD was neuropathologically
confirmed in only five (19%) patients (p = 0.017,
Fig. 1). The other neuropathologically confirmed VaD
patient was diagnosed during the clinical work-up as
probable AD/possible DLB and did not show clinically
relevant vascular disease according to the panel. Dur-
ing the seven month interval between inclusion in this
study and death, no clinically overt symptoms of stroke
had occurred in this patient.
The neuropathological diagnoses of five clinically
diagnosed probable VaD patients was definite AD
(n = 3) and definite DLB (n = 2). None of the cases that
were clinically diagnosed as probable VaD were neu-
ropathologically confirmed as VaD. Fourteen patients
were clinically diagnosed as probable AD+possible
VaD. However, neuropathologically, only two patients
were diagnosed as VaD whereas the others were
diagnosed as AD (n = 7), FTD (n = 4), and DLB
(n = 1). Lastly, eight clinical differential diagnoses
consisted of probable VaD with another probable
or possible dementia diagnosis, but only three of
these were true VaD based on the neuropathological
examination whereas the others were neuropatho-
logically diagnosed as AD (n = 3), FTD (n = 1) and
DLB (n = 1).
DISCUSSION
In this study, patients with vascular lesions on
structural brain imaging were often misdiagnosed
as suffering of dementia with a presumed clini-
cally significant vascular component as compared to
the autopsy-confirmed diagnoses. After neuropatho-
logical confirmation, the majority of these subjects
were diagnosed with other dementia types than VaD.
In particular, none of the patients clinically diag-
nosed as probable VaD were neuropathologically
confirmed as such. A clinical diagnosis of possible
VaD in combination with AD or another neurodegen-
erative brain disorder showed better correspondence
of clinical diagnosis with the neuropathological
diagnosis.
A possible explanation is that non-significant
cerebrovascular lesions (not contributing to patho-
physiology of the dementia syndrome) observed with
structural imaging of the brain were clinically over-
rated. Moreover, by using structural brain imaging only
to exclude other brain pathologies, neurodegenerative
brain disorders may be overlooked. From this point of
Table 1
Description of the population
Pathological diagnosis Statistical analyses
AD NONAD
Gender (% male/female) (n) 52/48 (42) 55/45 (29) p = 0.817
Age at inclusion (y) (n) 80.1 [ ± 9.0] (42) 71.0 [ ± 11.5] (29) p < 0.001
Age at death (y) (n) 82.0 [ ± 8.3] (42) 72.3 [ ± 11.3] (29) p < 0.001
MMSE (score out of 30) (n) 13.5 [ ± 6.3] (36) 16.0 [ ± 6.9] (23) p = 0.152
Interval inclusion and autopsy (y) (n) 1.7 [ ± 2.6] (42) 1.3 [ ± 1.6] (29) p = 0.944
Interval last clinical evaluation and autopsy (y) (n) 0.6 [ ± 1.7] (42) 0.5 [ ± 0.9] (29) p = 0.537
Data are mean [SD], percentage (%), or number (n).
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Fig. 1. Clinical diagnoses versus pathological diagnoses. The 27 clinically diagnosed cases with possible or probable VaD are subdivided into
the different pathological diagnosis [VaD (n = 5), AD (n = 13), DLB (n = 4), or FTD (n = 5)].
view, structural brain imaging served as a confounder,
leading to an overdiagnosis of VaD.
A promising approach that might overcome struc-
tural brain imaging being a potential confounder is the
use of biomarkers to diagnose dementia, including the
rating of hippocampal atrophy on brain MRI scan [17].
The inclusion of biomarkers in the revised research cri-
teria for AD diagnosis will significantly increase the
clinical diagnostic accuracy [17–19], as well as the
chance to identify AD pathophysiology in dementias
of mixed origin and also in prodromal AD [20–23].
However, the issue of judging whether cerebrovascular
lesions on structural brain imaging are pathophysio-
logically and clinically relevant, and thus, contribute
to the dementia syndrome will remain. Furthermore,
many factors that were identified as contributing to
CVD are frequently suspected as predisposing to AD
as well, and therefore mixed dementias are probably
underestimated [24].
The extensive use of CT scans (66%) compared
to MRI scans in this study could be a limitation of
this study. However, when imaging would only have
been performed by MRI, the proportion of misdi-
agnosed patients might have been increased to the
increased detection of non-relevant cerebrovascular
lesions as MRI is a more sensitive diagnostic method
[25]. Another limitation of this study is that the clinical
diagnosis was performed retrospectively, however, the
panel of neurologists was blinded to neuropathologi-
cal findings. Last but not least, the neuropathological
examinations were only performed on the right hemi-
spheres, and the fact that neuropathology is only a
relative gold standard, could be seen as limitations of
this study.
In conclusion, patients with vascular lesions on
structural brain imaging were often misdiagnosed
as possible or probable VaD as compared to the
autopsy-confirmed diagnosis. The majority of these
subjects were neuropathologically diagnosed with
other dementia types than VaD.
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